Name of journal: World Journal of Medical Genetics

ESPS Manuscript NO: 16286

Columns: Editorial

**Adeno-associated virus vectors for human gene therapy**

Chen H. AAV for human gene therapy

Haifeng Chen

**Haifeng Chen,** Virovek Incorporation, Hayward, CA 94545, United States

**Author contributions:** Chen H solely contributed to this paper.

**Conflict-of-interest:** Haifeng Chen is the Chiefe Executive Officer and owns stocks and/or shares in Virovek Incorporation.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Haifeng Chen, PhD, CEO** of Virovek Incorporation, 3521 Investment Blvd., Suite 1, Hayward, CA 94545, United States. haifengchen05@yahoo.com

**Telephone:** +1-510-887-7121

**Fax:** +1-510-887-7178

**Received:** January 8, 2015

**Peer-review started:** January 8, 2015

**First decision:** February 6, 2015

**Revised:** May 11, 2015

**Accepted:** May 16, 2015

**Article in press:**

**Published online:**

**Abstract**

Adeno-associated virus (AAV) is a small, non-enveloped virus that contains a single-stranded DNA genome. It was the first gene therapy drug approved in the Western world in November 2012 to treat patients with lipoprotein lipase deficiency. AAV made history and put human gene therapy in the forefront again. More than four decades of research on AAV vector biology and human gene therapy has generated a huge amount of valuable information. Over 100 AAV serotypes and variants have been isolated and at least partially characterized. A number of them have been used for preclinical studies in a variety of animal models. Several AAV vector production platforms, especially the baculovirus-based system have been established for commercial-scale AAV vector production. AAV purification technologies such as density gradient centrifugation, column chromatography, or a combination, have been well developed. More than 117 clinical trials have been conducted with AAV vectors. Although there are still challenges down the road, such as cross-species variation in vector tissue tropism and gene transfer efficiency, pre-existing humoral immunity to AAV capsids and vector dose-dependent toxicity in patients, the gene therapy community is forging ahead with cautious optimism. In this review I will focus on the properties and applications of commonly used AAV serotypes and variants, and the technologies for AAV vector production and purification. I will also discuss the advancement of several promising gene therapy clinical trials.

**Key words**: Adeno-associated virus; Baculovirus; Adeno-associated virus production and purification; Clinical trials; Gene therapy

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Adeno-associated virus (AAV) has become the first gene therapy drug approved by the Western world and spurred huge excitement in the gene therapy field. The gene therapy community is forging ahead with cautious optimism despite some challenges down the road. A battery of more than 100 AAV serotypes and variants are available and AAV production and purification technologies have become well established. Several clinical trials with AAV vectors have yielded exciting results. This paper will give you the information needed to understand the current development of the gene therapy field with AAV vectors.

Chen H. Adeno-associated virus vectors for human gene therapy. *World J Med Genet* 2015; In press

**INTRODUCTION**

With the approval of first adeno-associated virus (AAV)-based gene therapy drug, Glybera, to treat lipoprotein lipase deficiency (LPLD) by the European Union on November 2, 2012[1,2], human gene therapy entered a new era. It has been a long march from the first discovery of the AAV in the 1960’s, to the final approval of the first AAV-based gene therapy drug. The once-abandoned gene therapy field has now become a hotbed, with 11 different companies raising at least $618 million from venture capitalists and equity markets since the beginning of 2013. Top venture capital firms are among their backers, and some of the industry’s top talent is being attracted to what was once seen as a lost cause. The iShares Nasdaq Biotechnology Index is up 65% in 12 mo[3]. Basic research on AAV biology, vectorology, and gene therapy, since the first discovery of AAV, has generated much valuable information. More than 100 AAV serotypes and variants have been isolated and characterized. Some of them have been used for preclinical studies in a variety of animal models. Several AAV vector production technologies, especially the baculovirus-based technology have been established for commercial scale AAV vector production. AAV purification methods with density gradient centrifugation, column chromatography, or a combination of both, have been well developed towards commercialization. More than 117 clinical trials have been conducted with AAV vectors and yielded a vast amount of valuable information regarding the safety, efficacy, dosage, toxicity, immune response, biodistribution, and tropism of a few key AAV vectors, such as AAV2, and some Phase I/II clinical trials have yielded promising data. The gene therapy community is forging ahead with cautious optimism, although there are still challenges down the road, such as cross-species variation in vector tissue tropism and gene transfer efficiency, pre-existing humoral immunity to AAV capsids and vector dose-dependent toxicity in patients,. In this review I will focus on the properties and applications of several commonly used AAV serotypes and variants, and the technologies for AAV vector production and purification. I will also discuss the advancement of several promising gene therapy clinical trials utilizing AAV vectors.

**AAV SEROTYPES AND VARIANTS**

AAV is a single-stranded DNA virus of the *Dependovirus* genus of the *parvovirus* family with a genome size of about 5000 nucleotides. Its shell is about 25 nm in diameter, and is composed of 60 viral protein subunits arranged on a T = 1 icosahedral lattice[4]. The AAV genome encodes three open reading frames (ORFs), rep, cap, and AAP, flanked with inverted terminal repeats (ITRs) (Figure 1). AAV enters host cells via specific receptors on the cell surface. Once inside the cell, AAV uncoats and releases its genome, which is transported into the nucleus. The AAV genome integrates into the host chromosome 19 AAVS1 site[5,6] when no helper virus is present, or it replicates to produce progeny when a helper virus, such as adenovirus or herpes virus, is present. To make an AAV vector, the rep and cap sequences are removed and replaced with an expression cassette containing the target gene. When the AAV vector containing the target gene, together with the rep and cap sequences provided *in trans*, and helper virus (adenovirus, HSV, or baculovirus, *etc*.) are introduced into host cells under proper conditions, AAV vectors will be produced (Figure 2). Since the discovery of AAV in the 1960’s, now there have been over 100 AAV serotypes and variants isolated from adenovirus stocks or from human/nonhuman primates tissues and even some other mammals[7-11]. With their diverse tissue tropism, transduction efficiency and immunological profiles, these AAV vectors can be used to target various tissues for a variety of applications. The properties and applications of the conmmonly used AAV serotypes and variants are summariezed in Table 1.

***AAV1***

AAV1 has a genome size of 4718 nucleotides and exhibits high homology with those of other AAV serotypes. It appears that AAV6 was actuary generated through homologous recombination between AAV1 and AAV2. Studies show that sera from nonhuman primates with neutralizing antibodies (NAB) against AAV1 are more common than those from humans, whereas sera from humans with NAB to AAV2 are more common than those from nonhuman primates. AAV1 was more efficient for muscle[12], whereas AAV2 transduced liver more efficiently. High titers of NAB were detected for each vector administered to murine skeletal muscle, which prevented re-administering the same serotype but did not substantially cross-neutralize the other serotype. In the context of liver-directed gene transfer, similar results were observed except for a significant, though incomplete, neutralization of AAV1 from a previous treatment with AAV2[13]. Point mutations on the AAV1 capsid (S663A, S669A, and K137R) increased its transduction efficiency both in vitro and in vivo up to 6-fold[14]. Swapping the amino acids of AAV2 VP1 from 350 to 736 with the corresponding VP1 region of AAV1 gave rise to a hybrid vector that exhibited very similar properties to AAV1 in muscle both *in vitro* and *in vivo*. Analyses of smaller regions of the AAV1 VP1 amino acid sequence corresponding to the AAV2 capsid protein from additional mutants indicated that a small region of VP1 amino acids (from 350 to 430) functions as a major determinant of tissue tropism. Additional analysis demonstrated that both the major antigenic determinants and the heparin binding domain in the AAV capsid region were not required for efficient transduction of muscle by AAV1[15]. Due to its high efficiency in muscle transduction, AAV1 vectors have been used to study disease models such as Charcot–Marie–Tooth Neuropathy[16], congestive heart failure[17], Duchenne muscular dystrophy[18], *etc*., and in clinical trials to treat congenital heart failure[19-21]. The first gene therapy drug (Glybera) approved by the Western world to treat LPLD is based on AAV1[1,2].

***AAV2***

AAV2 is the most thoroughly characterized serotype. It has a genome size of 4675 nucleotides and contains inverted terminal repeats (ITRs) of 145 nucleotides, the first 125 nucleotides of which form a palindromic sequence[22]. Nearly all serotypes of AAV vectors use the AAV2 ITRs for AAV manufacture[23]. AAV2 requires heparan sulfate proteoglycan (HSPG) for cell attachment[24]. Among all the AAV serotypes discovered, AAV2 has the best transduction efficiency in cell culture[12] and therefore is the best tool for *in vitro* studies. The transduction efficiency of AAV2 vectors can be improved dramatically by point mutations (Y730F and Y444F) on the viral capsid[25].  Even though stable transgene expression mainly results from extra-chromosomal vector genomes in the liver, a series of studies has shown that vector genomes integrate into host chromosomes of hepatocytes at a low frequency preferentially into genes that are expressed in the liver[26].

All previous gene therapy studies in animal models and clinical trials were undertaken with AAV2 vectors. The earliest clinical trials with AAV2 vectors were for monogenic disorders. The first trial involved airway delivery (nasal, endobronchial, sinus and aerosol inhalation) of AAV2 vectors carrying cystic fibrosis transmembrane conductance regulator (AAV2-*CFTR*) in cystic fibrosis patients with mild lung disease[27]. The second set of trials involved intramuscular (IM) and hepatic delivery of AAV2 vectors carrying Factor IX gene in patients with hemophilia B[28]. AAV2 vectors have also been utilized in clinical trials for ocular diseases[29-31], and diseases involved the central nervous system[32-36].

***AAV3***

There are two subtypes of AAV3 and they were designated as AAV3A and AAV3B. They differ by only 16 nucleotides or 6 amino acids[37,38]. AAV3 has a genome size of 4726 nucleotides and has an overall sequence homology of 82% with AAV2. At the amino acid level AAV3 has a homology of 88% with the nonstructural (rep) proteins and 87% with the capsid proteins of AAV2. The major differences between AAV3A and AAV2 are that AAV3A lacks a typical TATA-box sequence at p40 promoter but contains the consensus binding sequence within the upstream region of the p5 promoter for adenovirus-related transcription factor E4F. These results imply that AAV3 contains serologically distinct structural proteins and its viral propagation may be controlled at the transcription level by different gene regulatory elements[37]. AAV3 requires heparan sulfate proteoglycan (HSPG) for cell attachment[39]. AAV3 vectors transduce human liver cancer cells extremely efficiently because they utilize human hepatocyte growth factor receptor (hHGFR) as a cellular co-receptor for viral entry and these cells express high levels of hHGFR. Both extracellular and intracellular kinase domains of hHGFR are required for AAV3 vector entry and AAV3-mediated transgene expression. The host cell proteasome machinery is responsible for AAV3 vector degradation and he transduction efficiency of AAV3 vectors is greatly improved with surface–exposed tyrosine (Y) to phenylalanine (F) mutations such as Y701F, Y705F or Y731F. AAV3 vectors with combined mutations such as Y705+731F show significant higher transduction efficiency than each of the single mutants in liver cancer cells *in vitro*. Direct intra-tumoral injection of AAV3 vectors in immune-deficient mouse xenograft models also result in high transduction efficiency of human liver tumor cells *in vivo.* The optimized AAV3 vectors carrying tyrosine-mutations result in increased efficiency of transduction following both intra-tumoral and tail-vein injections *in vivo* and AAV3 vectors carrying proapoptic genes may be useful for gene therapy of human liver cancer[40].

***AAV4***

AAV4 has a genome size of 4,767 nucleotides in length and contains an expanded p5 promoter region compared to AAV2 and AAV3[41]. The rep gene product of AAV4 shows greater than 90% homology to the rep products of AAV2 and AAV3, with none of the changes occurring in regions that had previously been shown to affect the known functions of Rep68 or Rep78. Most of the differences in the capsid proteins were thought to be located on the outer surface of the virus capsid. AAV4 can transduce human, monkey, and rat cells. A series of experiments including comparison of transduction efficiencies in a number of cell lines, competition co-transduction, and the effect of trypsin on transduction efficiency all suggest that the cellular receptor for AAV4 is different from that of AAV2[41].

AAV4 transduces ependyma with high efficiency when injected into the striata or lateral ventricles of adult mice[42]. AAV4 also efficiently transduces Type B astrocytes in the subventricular zone, and glia overlying the rostral migratory stream neural tube[43]. AAV4 vectors harboring a beta-glucuronidase gene administered unilaterally into the lateral ventricle mediated global functional and pathological improvements in of the mucopolysaccharidosis type VII (MPS VII) murine model that was caused by beta-glucuronidase deficiency[44]. AAV4 vectors carrying insulin-like growth factor-1 (IGF-1) or vascular endothelial growth factor (*VEGF*)-165 genes delivered in the cellular components of the ventricular system including the ependymal cell layer, choroid plexus [the primary cerebrospinal fluid (CSF)-producing cells of the central nervous system (CNS)] and spinal cord central canal lead to trophic factor delivery throughout the CNS, delayed motor decline and a significant extension of survival in SOD1(G93A) transgenic mice[45]. AAV4 vectors containing RPE65 gene delivered by subretinal injection into RPE65-/- purebred Briard dogs restore functional vision in the treated eye, with the untreated contralateral eye serving as an internal control[46]. A phase I/II clinical trial was conducted to assess the safety and efficiency of one subretinal injection with AAV4.rpe65.hrep65 vectors in the worse eye of patients with rpe65-/- retinal dystrophy[47].

***AAV5***

AAV5 has a genome size of 4642 nucleotides and is different from other parvovirus serotypes according to serological and DNA hybridization data[48]. Its DNA genome is similar to that of AAV2 in length and genetic organization. The AAV5 rep gene is 67% homologous to the *rep* gene of AAV2, with changes mainly occurring in the carboxyl and amino termini. The AAV5 ITRs are also different from the ITRs of other AAV serotypes. Though the Rep DNA binding site and the characteristic hairpin structure of AAV5 ITRs are retained, there is no consensus terminal resolution site. These differences in the ITR structures and the Rep proteins lead to the failure of cross-packaging between AAV2 and AAV5 as indicated by the inability to produce recombinant AAV particles. Analysis of alignment between the cap ORFs of AAV5 and other serotypes identifies both variable and conserved regions which could affect viral particle stability and tissue tropism. The failure of soluble heparin to inhibit AAV5 and the comparison of transduction efficiencies between AAV5 and AAV2 in a variety of cells lines show that AAV5 may use a different mechanism of uptake from AAV2[48].

A comparative *in-vivo* study with vectors based on AAV1, 2, 3, 4, 5, 6, and 8, and lentivirus (LV) indicates that AAV5 is the most efficient vector for transducing sensory neurons[49]. Even though AAV1, AAV5, and AAV6 all showed the most transduction of neurons two weeks after injection into the dorsal root ganglia (DRG), the time course of GFP expression from these three vectors studied from 1 to 12 wk after injection indicates that overall AAV5 was the most effective serotype, followed by AAV1. These two serotypes exhibited increasing rates of neuronal transduction at later time points, leading to over 90% of DRG neurons GFP+ at 12 wk with some injections of AAV5[49]. When delivered to the neocortex, hippocampus and cerebellum of twitcher mice, AAV5 carrying the galactocerebrosidase cDNA was effectively dispersed along the neuraxis of CNS as far as the lumbar spinal cord, and reduced the accumulation of psychosine in the CNS of *Twitcher* mice. Most importantly, the treated *Twitcher* mice were protected from loss of oligodendrocytes and Purkinje cells, axonopathy and marked gliosis, and had significantly improved neuromotor function and prolonged lifespan[50].

When delivered at low multiplicity of infection (MOI) to the apical surface of differentiated airway epithelia, AAV5 was 50-fold more efficient than AAV2 to mediate gene transfer. In transferring beta-galactosidase cDNA to murine airway and alveolar epithelia *in vivo*, AAV5 was also more efficient than AAV2, indicating that AAV5 vectors are good for mediating gene transfer to human and murine airway epithelia[51]. In addition, AAV5 vectors show a higher tropism for both mouse and human dendritic cells (DCs) than did AAV1, AAV2, AAV7, and AAV8 vectors[52]. Scientists at Virovek created a chimeric version of AAV5, named AAV5.2, by replacing the phospholipase A2 domain of AAV5 with that of AAV2. When both are produced in insect cells, the chimeric AAV5.2 shows much higher transduction efficiency than wild type AAV5 in a number of cell lines *in vitro* (unpublished data).

***AAV6***

AAV6 has a genome size of 4683 nucleotides in length and was isolated as a contaminant in a laboratory adenovirus stock, which appears to be related to AAV1 by sequence analysis[38]. The two ITR’s of AAV6 have different sequences, with the right repeat having a unique sequence and the left repeat identical to that of AAV2. Further analysis of the variable region of the cap gene revealed that AAV6 was 96% identical to AAV1 in that region, with only one amino acid change out of the 139-amino-acid translated sequence (a substitution of lysine-to-glutamate at position 531 of AAV6 VP1). Because of the 99% DNA sequence homology between AAV1 and AAV6, and the identical sequence of the first 508 nucleotides between AAV6 and AAV2, it was speculated that AAV6 may be derived from recombination between AAV1 and AAV2[13].

*In-vivo* studies show that AAV6 vectors are much more efficient than AAV2 in transducing epithelial cells in small and large airways, with as much transduction as 80% in some airways. This result indicates that AAV6 may have considerable advantages over AAV2 for gene therapy of lung diseases such as cystic fibrosis[53]. In addition, AAV6 exhibited body-wide transduction of the entire skeletal musculature through a single intravenous dose[54] and was used for gene therapy studies of Duchenne muscular dystrophy in mice[55]. Most of AAV vectors have poor transduction efficiency in blood cells. However, AAV6 with mutations on its surface-exposed serine (S) and threonine (T) residues (T492V + S663V) can efficiently transduce monocyte-derived dendritic cells[56], indicating its potential uses in dendritic cell gene therapy. AAV6 shows the best transduction efficiency in pancreatic beta-cells among AAV1, AAV2, AAV5, and AAV8 serotypes tested in this study. Nearly the entire islet population was gene transferred but with unique gene transfer efficiency and patterns when different delivery methods and vectors were used. Remarkably, localized gene delivery coupled with an insulin promoter allowed robust but specific gene expression in the beta-cells[57].

***AAV7***

AAV7 was isolated from rhesus monkeys and has a genome size of 4721 nucleotides[58]. Antisera generated to the other serotypes are not able to neutralize AAV7. AAV7 neutralizing antibodies are not common in human serum and low in activity when present. *In vivo* studies in mice indicate that AAV7 can transduce skeletal muscle at similar efficiency to AAV1[11]. While in mouse liver AAV8 out-performs AAV7, in nonhuman primate liver, expression from AAV7 vector stabilized at higher levels than AAV8, indicating that AAV7 should be considered a preferred vector for gene transfer in the primate liver[58]. In nonhuman primates, AAV7 can direct as efficiently as AAV9 a robust and widespread cellular transduction in the central nervous system and other peripheral neural structures[59]. AAV7 has also been used to target neurons within the Basal and Lateral Amygdala (BLA) area and shows a trend toward having the highest efficiency of transduction[60].

***AAV8***

AAV8 was isolated from rhesus monkeys and its rep and cap coding region was fully sequenced but the rest of the genome has not been analyzed. The rep and cap sequences of AAV-8 are 88% homologous to AAV7 and 82% homologous to AAV2 in nucleotides[11]. Between AAV8 and AAV2, the most significant structural differences are located at protrusions surrounding the 2-, 3-, and 5-fold axes on the capsid surface. Amino acid residues on those axes were reported to control antibody recognition and transduction efficiency for AAV2. Furthermore, comparing the amino acids on capsid surfaces between AAV8 and AAV2 revealed that the distribution of basic charge for AAV8 at the region corresponding to AAV2 heparin sulfate receptor binding motif was reduced. This results were consistent with the observation that AAV8 is a non-heparin-binding phenotype[61].

AAV8 exhibits remarkably greater transduction efficiency in liver than those of other serotypes[11]. This high transduction efficiency in liver and low cross-reactivity to antibodies against other human AAV’s have led to great efforts in developing AAV8 as a viral vector for gene therapy of liver-targeted applications. Using AAV8 in mouse models as a gene therapy vector for long-term correction of hemophilia A, familial hypercholesterolemia, and glycogen storage disease type II has been reported[62-64]. AAV8 has also been used successfully in a canine model for liver-targeted gene therapy[65]. In mice and hamsters, AAV8 has been shown to be able to cross efficiently the barrier of blood-vessel to gain systemic gene transfer in both cardiac and skeletal muscles[66]. In mouse model, AAV8 has also been used successfully to target the pancreas[57]. However, recent data indicate that AAV8 vectors, which are very effective in many animal models, transduced human hepatocytes rather poorly, - approximately 20-fold less, when compared to its transduction efficiency in mouse hepatocytes[67].

Scientists at Virovek created a chimeric version of AAV8, named AAV8.2, by replacing the phospholipase A2 domain of AAV8 with that of AAV2. When both are produced in insect cells, the chimeric AAV8.2 shows much higher transduction efficiency than wild type AAV8 both *in vitro* and *in vivo* (unpublished data).

***AAV9***

AAV9 was isolated from human tissues and its genome was not fully sequenced except the rep and cap coding sequences[68]. AAV9 capsid differs from AAV4 in nine variable surface regions (VR-I to -IX), but differs AAV2 and AAV8 in only three (VR-I, VR-II, and VR-IV). The difference in VR-I region modifies the raised region of the capsid surface between the 2-fold and 5-fold depressions. The difference in VR-IV produces smaller 3-fold protrusions in AAV9 that are less “pointed” than AAV2 and AAV8. Remarkably, residues in the VRs of AAV9 have been identified as important determinants of cellular tropism and transduction and distinguish AAV9’s antigenic diversity from AAV2[69].

AAV9 was reported to provide global cardiac gene transfer stable for up to 1 year in mouse or rat that was superior to other serotypes such as AAV1, AAV6, AAV7, and AAV8[70]. AAV9 transduced myocardium 5- to 10-fold higher than AAV8, resulting in over 80% cardiomyocyte transduction after tail vein injection in mice[71]. In large animal model such as pigs, treatment with AAV9 carrying the small calcium-binding protein S100A1 prevented and reversed functional and structural changes by restoring cardiac S100A1 protein levels. AAV9-S100A1 treatment normalized cardiomyocyte Ca(2+) cycling, sarcoplasmic reticulum calcium handling, and energy homeostasis[72].

When delivered systemically and intra-cerebrospinally, AAV9 has also been reported to obtain widespread gene delivery to the CNS. Delivering AAV9-GFP in the cisterna magna of both newborns and young cats indicated that high levels of motor neurons (MNs) from the cervical (84% ± 5%) to the lumbar (99% ± 1%) spinal cord were transduced, which demonstrates that the age at CSF delivery does not affect significantly AAV9 tropism for MNs[73]. AAV9 can transduce brain’s antigen-presenting cells (APC) and trigger a full immune response that mediates significant brain pathology, depending on the transgene immunogenicity. These observations raise concerns that foreign-proteins expressed at certain level may be able to trigger both humoral and cell-mediatedresponses, which may complicate preclinical toxicology studies[74].

A clinical trial of AAV9 vectors carrying human spinal muscular atrophy (SMN) gene has been initiated in early 2014 for treatment of SMN in infants[75].

***AAVShH10***

AAVShH10 is derived from a shuffled library closely related to AAV6 and is capable of efficient, selective Müller cell infection through intra-vitreal injection. Remarkably, AAVshH10 exhibits significantly improved transduction efficiency relative to AAV2 (> 60%) and AAV6[76]. AAV-ShH10 has been employed to overexpress GDNF from Müller cells and thereby significantly slow the rate of retinal degeneration in a rat model of autosomal dominant *Retinitis Pigmentosa*[77]. AAVShH10 delivery through intra-vitreal injection can transduce Müller cell in a significantly different pattern in   Dp71-null mice with a compromised blood-retinal barrier (BRB), indicating that there are changes in viral cell-surface receptors as well as differences in the permeability of the inner limiting membrane in this mouse line. However, the compromised BRB of the Dp71-null mice does not lead to virus leakage into the bloodstream when the virus is injected intra-vitreally - an important consideration for AAV-mediated retinal gene therapy[78].

***AAV7m8***

AAV7m8 was isolated from a mixture of three libraries that went through several rounds of *in vivo*–directed capsid evolution. AAV7m8 is a genetic variant of AAV2, with a peptide inserted on its heparin-binding site[79]. AAV7m8 is able to trasport the gene payload to the outer retina after injection into the eye’s easily accessible vitreous humor and mediates widespread gene expression to the outer retina, which rescued the disease phenotypes of Leber’s congenital amaurosis and X-linked Retinoschisis in corresponding mouse models. In addition, AAV7m8 is able to transduce primate photoreceptors when delivered via the vitreous, expanding its therapeutic promise[79]. AAV7m8 encoding channel rhodopsin under the ON bipolar cell–speciﬁc promoter mediates long-term gene expression restricted to ON-bipolar cells after intra-vitreal administration. Channel rhodopsin expression in the ON-bipolar cells leads to restoration of ON and OFF responses at the retinal and cortical levels. Moreover, light-induced locomotor behavior is restored in treated blind mice[80].

***AAVDJ***

AAVDJ is a chimera derived from AAV2, AAV8, and AAV9, differentiated by 60 amino acids from its closest natural relative AAV2 in the capsid. It was isolated through an adapted DNA family shuffling technology. AAVDJ outperformed eight standard AAV serotypes (AAV1, 2, 3, 4, 5, 6, 8, and 9) in cultures of 10 cell lines and greatly surpasses AAV2 in livers of IVIG-immunized and naïve mice[81].

***Self-complementary AAV genomes***

Native AAV packages single-stranded genomes[82,83] and requires host-cell factors to synthesize the complementary strand before transcription can be initiated. However, when the single-stranded genome is less than half wild-type size, AAV can package either two copies, or dimeric inverted repeat DNA molecules[84]. These dimeric inverted repeat DNA molecules can spontaneously anneal and form self-complementary molecules once uncoated inside the host-cell[85]. Packaging of self-complementary AAV (scAAV) or sometimes called double-stranded AAV (dsAAV) genomes, can be made more efficient by deleting the terminal resolution site (trs) or the D-sequence (the packaging signal) together with the trs from one AAV terminal repeat[86,87]. The important trade-off for scAAV vectors is the loss of half the coding capacity. However, small protein-coding genes (up to 55 kd), and any currently available RNA-based therapy can be accommodated.

These scAAV vectors exhibit fast onset and enhanced AAV transduction efficiency and have been widely used in many gene therapy studies. Wang *et al*[87] reported that scAAV vectors dramatically improved transduction efficiency in more than 20 cell lines of human, monkey and rodent origins and accelerated long-term transduction *in vivo* in mice when delivered via intramuscular or tail vein injections. Nathwani *et al*[88] reported a 20-fold improvement in hFIX expression from scAAV in mice over comparable ssAAV vectors. It has been reported that a single intravenous injection of scAAV9 vectors carrying U7ex23 (small nuclear RNAs) in the utrophin/dystrophin double-knockout (dKO) mouse restored the dystrophin expression to near-normal levels in all muscles examined, including the heart. This resulted in a considerable improvement of their muscle function and dystrophic pathology as well as a remarkable extension of the dKO mice lifespan[89]. Yang *et al*[90] reported that expression of miRNA from scAAV inhibited the replication of cell culture–propagated HCV (HCVcc) by 98%, and resulted in up to 93% gene silencing of RLuc-HCV reporter plasmids in mouse liver, indicating the combination of an AAV vector delivery system and exploitation of the endogenous RNAi pathway is a potentially viable alternative to current HCV treatment regimens.

**AAV VECTOR PRODUCTION**

There are several technologies available for production of AAV vectors. These include transient plasmid transfection, adenovirus infection, stable-cell lines harboring AAV helper functions, HSV infection/transfection, and baculovirus infection technologies. All these technologies have the common elements for AAV vector manufacturing: (1) target gene flanked by ITRs, which in most cases are derived from AAV2; (2) AAV rep and cap genes provided *in trance*, in which the rep gene is derived from AAV2 while the cap gen can be of any serotypes; and (3) helper functions from adenovirus, HSV, or baculovirus. When these three components are introduced into a host cell under proper conditions, AAV vectors will be produced (Figure 2). Each of the technologies has unique properties to suit specific applications.

***Plasmid transfection of mammalian cells***

Initially, AAV vectors were produced by infection of mammalian cells with a wild type adenovirus and a recombinant adenovirus carrying AAV rep and cap genes followed by transfection with plasmid carrying the target gene flanked by AAV2 ITRs[91]. This method produced large quantities of adenoviruses that had to be removed. Although purification removes most of the contaminating adenoviruses, and heat treatment inactivated the remainder, the AAV vector preparations were still contaminated with adenovirus proteins capable of causing host immune response. In order to eliminate the adenovirus from AAV vector production, two groups at about the same time reported the use of adenovirus-free system to produce AAV vectors[92,93]. They used three plasmids, one harboring adenovirus VA, E2A and E4 genes, the second harboring AAV rep and cap genes, and the third harboring target gene flanked by two AAV2 ITRs. After transfection of these plasmids mediated by calcium phosphate into HEK-293 cells, which contained stably integrated adenovirus *E1* genes, AAV vectors were produced free of adenovirus. Later, the method was stream-lined to contain only two plasmids, one with the target gene flanked by two AAV2 ITRs and the other with AAV rep and cap genes as well as the required adenovirus helper genes. AAV vectors were produced by transfecting both plasmids into HEK-293 cells[94]. The advantages of plasmid transfection, whether with two or three plasmids, to produce AAV vectors are that it requires substantially less time and is fairly easy to perform compared with other systems such as recombinant HSV or baculovirus systems. It can produce small-scale AAV vectors enough for *in-vitro* assays and small animal studies and is still widely used by many academic labs. The disadvantages are that it is difficult to scale up due to the inherent property of adherent cells and use of animal serum, which is not favored by FDA. Lock *et al*[95] reported that typical yield of AAV vector production from forty 15-cm plates is about 1 to 2 × 1013 vg.

In order to increase production scale, HEK-293 cells were adapted to suspension culture and transfection was performed with polyethylenimine (PEI) to produce AAV vectors. The AAV vector production yields range from 5 × 1012 vg/L in serum-containing suspension culture[96] to 2.85 × 1013 vg/L in serum-free suspension culture[97].

***Stable-cell line harboring AAV helper functions***

One of the methods to produce AAV vectors is to employ cell line stably harboring AAV helper genes. In some cases, only AAV rep/cap genes were stably integrated into mammalian cells and AAV vectors were produced upon infection of the cell lines with a wild-type adenovirus followed by transfection with AAV vector plasmid or infection with a second adenovirus carrying target gene flanked by two AAV ITRs[98-103]. In one case, both AAV rep/cap genes and AAV vector plasmid were stably integrated into the cell line for AAV vector production[99]. AAV production yield with stable cell line system was up to 1 × 104 vg/cell. Stable cell line systems require adenovirus co-infection for AAV vector production, which is not a desirable feature and posts downstream challenges for AAV purification. In addition, stable cell lines tend to lose integrated genes after frequent passages and AAV production yields tends to decrease with the increase of cell passage number. Another drawback is that it takes several months to establish and characterize a stable cell line.

***HSV-based systems***

The first generation HSV-based method for AAV vector production was developed by Conway and colleagues, which depended on an amplicon system[104]. The AAV2 rep and cap genes and their native p5, p19, and p40 promoters were cloned into a plasmid that carries the HSV origin of replication and packaging signal. To produce HSV viruses carrying the AAV2 rep and cap genes, Vero cells with either wild-type HSV DNA or infected with wild-type HSV were transfected with the resulting pHSV-RC plasmid. The missing *trans* helper genes required for HSV amplicon DNA replication and packaging into HSV particles were provided by the wild type HSV. During this process, HSV particles generated both from amplicon and wild-type HSV sources were further ampliﬁed through serial infection passages. Finally, HSV-RC stocks were used to produce rAAV vectors by infecting either proviral cell lines that contained an integrated rAAV-2 genome or cells transfected with a rAAV2 plasmid or infected with rAAV2. This amplicon system has disadvantages such as the requirement of three components (HSV-RC, wild type HSV, and rAAV), the undesirable safety concern of wild-type HSV, and the dominant amplification of wild type HSV that is toxic to the producer cells. It was reported in the same study that use of a mutant HSV instead of wild type HSV produced higher titer of rAAV because of its lower cytotoxicity.

In order to increase AAV production yield, a second generation of HSV-based system was developed in which the AAV rep/cap gene was cloned into one replication-deficient HSV and the gene of interest flanked by ITRs was cloned into a second replication-deficient HSV[105]. Upon dual infection of HEK-293 cells with these two rHSV vectors, AAV vectors were produced with yields as high as 1.55 × 1012 vg/flask with 1 × 107 cells. This system was further scaled up in cell factories to produce AAV-AAT in serotypes 1 and 9. This method was able to produce more than 8.5 × 1013 AAV1 vg (8.5 × 104 vg/cell) from one cell factory[106]. The problem with this system is that the production of high-titer and infectious replication-deficient HSV vectors is very challenging due to the fact that: (1) the production efficiency and the profile of product safety are usually inversely correlated, since rendering HSV vectors replication incompetent by genetic deletions also typically reduces rHSV yield; and (2) HSV particles are very sensitive to production and processing conditions such as temperature, shear, solvents, and detergents and can easily be inactivated during manipulation.

***Baculovirus-based systems***

Production of AAV vectors in insect cells was first pioneered by Urabe *et al*[107]. In this system, the AAV2 rep78 was cloned under control of a deleted version of baculovirus early promoter (E1) and rep52 under control of p10 promoter in a head-to-head orientation. The AAV2 capsid gene was cloned under control of baculovirus polyhedrin (polh) promoter and the VP1 start codon ATG was mutated into ACG to diminish the translation efficiency so that the ribosome machinery can scan down to next low efficiency ACG for VP2 expression and then scan further down to the start codon ATG of VP3 for highly efficient expression[107]. The production yield of this system has been reported up to 5 × 104vg/cell. Though the AAV production yield is increased compared to plasmid transfection systems, there are two flaws with this system: (1) the rep78 sequence contains 100% of rep52 sequence, which renders the rep containing baculovirus unstable due to homologous recombination between rep78 and rep52 as demonstrated by Kohbrenner and colleagues[108]; and (2) the VP1 level is lower than normal due to the ATG-to-ACG mutation, which results in less infectious AAV vectors.

In order to make this system more stable, Smith *et al*[109] mutated the rep78 start codon ATG into ACG and subsequent nine in-frame ATGs into non-start codons, but retained the start codon ATG for rep52. This modification enabled the expression of both rep78 and rep52 from a single rep78 coding sequence and made the baculovirus more stable. However, the VP1 retained the same suboptimal ACG start codon, which resulted in suboptimal VP1 expression. This modified system produced AAV vectors up to 7 × 104 vg/cell. Several research groups reported that the AAV vectors produced in insect cells with suboptimal VP1 expression were less infectious than that produced in mammalian cells and that increasing the VP1 expression improved the infectivity of AAV vectors[108,110-112]. Urabe and colleagues also reported in their patent (US 8163543 B2) that increasing VP1 expression levels improved AAV vector infectivity.

Researchers from both UniQure and NIH scaled up this system into 200 liter bioreactor using the baculovirus-infected insect cells (BIIC) method[113]. By using conditions established with small-scale cultures, AAV was produced in larger volume cultures. Consistent AAV yields were attained in cultures ranging from 10 liters to 200 liters. Based on the final yield, each cell produced 18000 ± 6800 particles of purified AAV in 10-, 20-, 100-, and 200-liter cultures. Thus, with an average cell density of 4.32 × 106 cells/ml, ≥ 1016 purified AAV particles are produced from 100 to 200 liters. The downstream process resulted in about 20% recovery estimated from comparing the quantities of capsid protein antigen in the crude bioreactor material and in the final, purified product.

Researchers at Genethon reported a modified baculovirus system for AAV vector production (patent application WO 2013/014294 A2). They made two versions of baculoviruses, one with the *cathepsin, chitinase*, and *p10* gene disrupted, and the other with the *cathepsin, chitinase*, p26, p10, and p24 genes disrupted. The AAV rep2/cap8 cassette and the murine embryonic alkaline phosphatase (mSEAP) reporter gene flanked by AAV2 ITRs were respectively cloned into the polyhedrin region. Their results showed that, even though the disruption of *cathepsin, chitinase*, p26, p10, and p24 genes did not improve the AAV production yield, it indeed improved the infectivity of the AAV vectors 2- to 4-fold due to the reduction of AAV capsid protein degradation possibly caused by the protease *cathepsin*. The AAV vector production yield with this modified system ranges from 1.31 × 1011 vg/mL (or 1.31 × 1014 vg/L) to 2.09 × 1011 vg/mL (or 2.09 × 1014 vg/L).

In our laboratory we made two important modifications to the baculovirus-based system: (1) an artificial intron harboring the *polh* promoter was inserted into the AAV rep78 coding sequence at the p19 promoter region such that both the rep78 and the rep52 can be expressed from a single rep coding sequence; and (2) the same artificial intron containing the *polh* promoter was inserted into the AAV VP1 coding sequence upstream of the VP2 start codon such that all three capsid proteins (VP1, VP2, and VP3) can be expressed from a single capsid gene without the need to mutate the VP1 start codon ATG into suboptimal start codons[112]. This is the only baculovirus-based system with VP1 coding sequence that retains the authentic optimal ATG start codon. These modifications not only make the baculovirus more stable due to the elimination of rep sequence repeats, but also restore the infectivity of AAV vectors produced in insect cells because of the optimal VP1 expression level. It is well known that the VP1 protein contains a phospholipase A2 domain required for AAV infectivity and that decreased level of VP1 protein in the virus particle renders the virus less infective[114-116].

We made additional improvement to our baculovirus-based system in order to produce AAV vectors carrying toxic genes at a normal level[117]. Recombinant viruses carrying toxic genes such as *diphtheria* toxin, *Pseudomonas* exotoxin, ricin, and barnase are extremely difficult to produce since trace amount of toxin expression can kill the producer cells. We exploited the difference in intron splicing machineries between insect and mammalian cells. By inserting a mammalian intron that is not recognized by insect cells to disrupt the ORF of the toxin gene carried by the recombinant virus, we are able to abolish toxin expression during virus production but restore expression once the recombinant virus is introduced into mammalian cells. In this improved system, recombinant baculovirus carrying the toxic gene can be produced at normal levels. By using this recombinant baculovirus harboring the intron-interrupted toxin gene, we are able to produce AAV vectors up to 1.81 × 1015 vg purified from each liter of culture, 10- to 100-fold higher than with other AAV production systems. Recently we performed a 25-liter production run in the Wave Bioreactor 20/50EH system, and obtained 3.50 × 1016 vg of total purified AAV6 vectors and the yield was independently verified by a third party (unpublished data).

AAV manufacturing technologies have sufficiently advanced such that we now have a robust system to produce AAV vectors with yields that exceed 1 × 1015 vg per liter, or 1 × 1018 vg from 1000-liter bioreactor, which will be able to meet the demand of treating ten thousand patients at a dosage of, say, 1 × 1014 vg/patient.

**AAV PURIFICATION**

There are several methodologies to purify AAV vectors from cell cultures. They include density gradient ultracentrifugation, column chromatography, and chloroform extraction/PEG precipitation partitioning. Virus particle purification by density gradient ultracentrifugation with cesium chloride (CsCl) has been used for more than 50 years[118,119]. When subjected to a strong centrifugal ﬁeld, CsCl in solution forms a density gradient and viruses that are centrifuged to equilibrium in CsCl are separated from contaminants and collected in bands based on their buoyant densities. The history of chromatography spans from the mid-19th century to the 21st. Column chromatography is a well-established method for efficient and scalable purification of biomolecules and has been used for AAV vector purification[120-124]. Chloroform extraction/PEG precipitation partitioning for AAV vector purification is rather new and not widely used yet.

***Density gradient ultracentrifugation***

The common strategy for AAV puriﬁcation through ultracentrifugation starts with infected cell lysis and DNA digestion. The cell lysate is cleared by centrifugation to remove cell debris and applied to a discontinuous CsCl step-gradient with 1.3 g CsCl/mL on the top and 1.5 g CsCl/mL on the bottom. Since the AAV particles have a buoyant density of 1.4 g/mL, they are able to be separated from protein contaminants after the first round of centrifugation, and collected as a single band in the middle of the gradient. The harvested AAV band is then mixed with 1.4g CsCl /mL and subjected to a second round of isopycnic gradient ultracentrifugation. Since they all have the same buoyant density, this method can be used to purify all different serotypes of AAV vectors. In our lab, we have used this method to purify many serotypes of AAV vectors ranging from 1 × 1013 vg to 3 × 1016 vg per production run and obtained satisfactory results. The advantage of this method is its versatility because this one process can be used for any serotype. The recovery rate is generally more than 70% and purity is more than 98% as judged by SDS-PAGE gel (Figure 3).

Although some researchers reported that CsCl has deleterious effect on AAV vector infectivity[121,125], we performed a side-by-side comparison between CsCl and iodixanol purified AAV1-GFP vectors and have not seen any difference in infectivity (unpublished data). Ayuso *et al*[126] optimized the CsCl protocol by incorporating differential precipitation of AAV particles with polyethylene glycol and produced AAV vectors in higher yield and markedly higher vector purity, which correlating with better transduction efficiency detected with several AAV serotypes in multiple tissues and species. In fact, the Center for Cellular and Molecular Therapeutics at the Children Hospital of Philadelphia (CHOP) is using a combination method to purify AAV vectors under cGMP conditions in which a column chromatography is used to capture AAV and CsCl ultracentrifugation is used to separate the empty from the full AAV particles[127], which indicate that AAV vectors purified by CsCl ultracentrifugation method are acceptable for clinical usage.

Iodixanol, an X-ray contrast compound, can be used as a density gradient medium in place of CsCl. Zolotukhin *et al*[125] reported the use of iodixanol medium combined with chromatography for AAV vector purification and obtained over 50% recovery with 99% purity. Hermens *et al*[128] reported the use of iodixanol to replace CsCl for purification of AAV vectors and shortened the centrifugation period to 3 h with reproducible concentration and purity of AAV vector stocks. In our laboratory, we used iodixanol to replace CsCl for AAV purification and obtained similar recovery rates and purity as with CsCl.

***Column chromatography***

The modes of column chromatography suitable for AAV purification include affinity, ion exchange, gel filtration and hydrophobic interaction. Several optimized chromatographic steps are required to obtain virus of high yield and purity. Optimal AAV purification protocols generally include two chromatographic steps or a combination of chromatography with ultracentrifugation/filtration. Because different AAV serotypes have different compositions on the surface of viral particles, specific resins should be used for purification. Heparin-based affinity column chromatography has been used for AAV2 vector purification due to the fact that AAV2 uses heparin sulfate proteoglycan as its receptor[24]. Gao *et al*[121] reported the use of a fully closed two-column chromatography system to purify AAV vectors. Yields of AAV vectors purified by this method are high, potency is increased, and the purity of column-purified preparations is substantially improved. Brument *et al*[129] developed a two-step chromatography protocol on the basis of using ion exchange resins. Average recovery rate is 33%. *In-vitro* and *in-vivo* data demonstrated that this protocol, which does not need any pre-purification of the cell lysate, can be used to obtain highly pure AAV2 and AAV5 stocks. AVB resin has also been used to purify AAV vectors[109]. Based on published data, on average the recovery rate of AAV purification with column chromatography is around 30%, which is substantially lower than the recovery rate (70%) of CsCl method used in our laboratory. In addition, commonly used column chromatography methods cannot remove empty AAV capsids from the fully packaged virus particles. Though Qu *et al*[130] succeeded in using ion-exchange chromatography alone to separate empty and full particles from a semi-purified mixture of partially purified AAV, co-author Dr. Wright at CHOP has adopted a combinational method of column chromatography to capture AAV followed by CsCl gradient centrifugation, which allows his group to separate empty from full particles for their cGMP material purification[127].

***Chloroform extraction, PEG precipitation and partitioning***

Alternative methods for AAV vector purification have also been developed. Wu *et al*[131] reported chloroform treatment, PEG/NaCl precipitation and a final chloroform extraction to purify AAV vectors and obtained greater than 95% purity. The whole procedure can be performed in 4 h without using ultracentrifugation or chromatography equipment. Another method was reported by Guo *et al*[132] in which AAV vectors from culture media and cleared cell lysate were precipitated with PEG8000/NaCl, and the pellet was resuspended in Hepes buffer, followed by chloroform extraction and PEG/salt partitioning. AAV vectors were purified and showed infective in both *in vitro* and *in vivo* studies. However, these methods have not been widely used yet.

**CLINICAL TRIALS**

To date, there have been over 2076 gene therapy clinical trials worldwide, in which approximately 5.9% (over 127 clinical trials) have used AAV vectors[133]. Two general delivery methods have been employed to treat diseases with AAV vectors. Local delivery (surgical injection) method is used to treat diseases that affect specific organs. Systemic delivery (intravenous injection) method is used to treat diseases that affect all cells, such as lysosome storage diseases[134], and muscular dystrophies[54]. Many eye diseases, for example, are treated with either intra vitreal injection by primarily affecting retinal neurons or sub-retinal injection by placing virus in contact with the photoreceptor and retinal pigmented epithelial (rpe) layers of the eye[135]. Local delivery of AAV into the heart has been used to treat cardiac diseases[136]. Similarly, delivering AAV into the target region with stereotactic surgery can be used to treat some neurodegenerative diseases that primarily affect a particular region of the brain (striatum), such Parkinson’s disease[137,138]. As a result, many promising data have been obtained from Phase 1 and Phase 2 clinical trials for a number of diseases in recent years.

***Leber’s congenital amaurosis***

Leber’s congenital amaurosis (LCA) is an inherited retinal disease that causes severe visual impairment in infancy or early childhood. Three groups of investigators reported the use of AAV2 to treat homozygous recessive *rpe65* deﬁciency successfully in their clinical trials. The *rpe65* codes for a protein that is responsible for regenerating 11-*cis* retinal in the retinal pigmented epithelial cell layer of the eye, and lacking this rpe65 protein the patient is essentially blind in low light. In these three independent phase 1 clinical trials, each patient was injected sub-retinally into one of the eyes with the rAAV-*rpe65* vector[29-31]. Studies of gene expression in the portion of the treated eye demonstrated that virtually 100% of the remaining photoreceptor cells were corrected and remarkable recovery of vision was seen in these patients[139]. The positive results from these *rpe65* clinical trialsindicate that essentially any recessive genetic defect in the eye with loss-of function should be able to be corrected. Studies for a variety of other eye diseases with genetic defects, as well as diseases such as macular degeneration are now underway.

***Hemophilia B***

Hemophilia B is a rare bleeding disorder in which blood doesn’t clot normally due to mutations in the gene for coagulation factor IX. A few clinical trials have been conducted for this factor IX deﬁciency. Patients lacking factor IX, a serum protein that is an essential component of the blood clotting cascade, experience increased episodes of bleeding in response to mild trauma or spontaneous hemorrhage in joints and muscle. The two initial hemophilia B phase I/II clinical trials, injecting AAV2 with a factor IX cDNA to skeletal muscle or liver, exhibited no serious adverse events[28,140,141]. Even though the muscle trial did not achieve a therapeutic level of factor IX in the circulation, long-term expression of clotting factor was detected on muscle biopsies taken up to 3 years after vector injection. AAV delivery to liver via the hepatic artery determined a therapeutic dose, which agreed closely with the doses predicted by studies in hemophilic dogs. However, the expression of factor IX in the treated patients lasted for only a period of weeks, followed by a gradual decrease in factor IX levels accompanied by a self-limited, asymptomatic rise and fall of liver enzymes[142].  The loss of expression was associated with a cytopathic T cell (CTL) response to AAV capsid protein but not the transgene. More recently, a new phase I clinical trial for hemophilia B was conducted. This time AAV8 vectors carrying a codon-optimized, self-complementary factor IX cassette were used[143]. The AAV8 vectors were delivered intravenously and dose-dependent and stable expression of therapeutic levels of factor IX in serum at middle and high vector doses were observed. Expression was stable over 6 mo of follow-up, and several patients no longer found it necessary to infuse factor IX protein. Similar to earlier hemophilia B trials, some patients appeared to mount an inﬂammatory response, as determined by increased levels of serum alanine aminotransferase. After a short course of an immune modulator (prednisolone), these patients recovered a normal enzyme proﬁle and retained therapeutic levels of factor IX after immunosuppression was stopped.

***Congestive heart failure***

In 2007, the first clinical trial for heart failure was launched in the United States[20,21]. This Phase 1/2 multicenter trial was designed into two parts to evaluate the safety and the biological effects of AAV1.SERCA2a intracoronary delivered into patients with advanced heart failure. In part 1 of the trial, an satisfied safety profile was observed in the 12-mo follow-up with these patients[20,21]. Several patients showed improvement as measured by biomarker (two patients), functional (four patients), symptomatic (five patients), and LV function/remodeling (six patients) parameters. These results indicated that treatment with AAV1.SERCA2a provides quantitative biological benefit.

Thirty-nine patients with advanced heart failure were enrolled in part 2 of the trial and randomly divided into four groups, in which three groups received intracoronary AAV1.*SERCA2a* (low dose: 6e+11 DRP, middle dose: 3e + 12 DRP, and high dose: 1e+13 DRP) and one group placebo[144]. Over six months of the trial, patients’ symptoms including Minnesota Living With Heart Failure Questionnaire (MLWHFQ) and New York Heart Association (NYHA) score, echocardiographic measures, NT proBNP levels, and functional status [six-minute walk test (6MWT) and VO2 max], were evaluated. Based on the above end-points, clinical outcomes and concordant trends among groups and patients were compared to determine the success of treatment. At the group and individual patient levels, the high-dose group met the pre-specified criteria for success. Patients treated with AAV1.SERCA2a showed improvement or stabilization in MLWHFQ and NYHA scores, NT proBNP, 6MWT, and VO2 max levels, and LV end-systolic volumes at 12 mo when compared with patients treated with placebo. In the placebo group over a one-year period, cumulative recurrent cardiovascular events (myocardial infarction, cardiac transplantation, LV assist device insertion, heart failure admission, and death) increased. The patients treated in the high dose group continued to perform significantly better at 12 mo when compared with patients in the rest of groups by showing no increase of adverse events, disease-related events, laboratory abnormalities, or arrhythmias. Though the patient groups with low- and middle-dose of AAV1.SERCA2a had decreased recurrent cardiovascular events for the first six months, they had events that were similar to placebo group from 6 to 12 mo[144].

***Parkinson’s disease***

Since 2003, a total of nine clinical trials have been conducted for gene therapy of Parkinson’s disease (PD) with AAV vectors[145]. PD is a chronic and progressive neurodegenerative disease that is most widely diagnosed for the profound degeneration of mid-brain dopamine nigrostriatal neurons linked to serious motor symptoms. In the hope of preventing neurodegeneration and increasing dopamine neuron synapses, Bartus *et al*[137] used AAV2 to deliver a neurotrophic factor, neurturin, to striatal tissue of PD patients. Though they observed some evidence of improvement, they did not reach their primary therapeutic end points due to the lack of sufficient nigral neurons to show a significant effect. Christine *et al*[32] overexpressed aromatic amino acid decarboxylase, the final enzyme in the dopamine synthetic pathway and also observed some improvement clinically and demonstrated clearly continuous gene expression over time.

***Alzheimer disease***

Alzheimer’s disease (AD) is a neurodegenerative disorder. Though the cause and progression of AD is not fully understood, it is well recognized that the function and survival of basal forebrain cholinergic neurons that are vulnerable in AD can be enhanced by nerve growth factor (NGF). Encouraging clinical trial results have come from a study in which AAV2 vectors carrying human NGF gene was used to treat AD through stereotactic surgical delivery in the hippocampus[146,147]. The results indicated that[147] AAV2-NGF was safe and well-tolerated for 2 years. No evidence of accelerated decline was observed through positron emission tomographic imaging and neuropsychological testing. Long-term, targeted, gene-mediated NGF expression and bioactivity were confirmed in the brain autopsy tissues. This clinical trial provides important evidence that bilateral stereotactic administration of AAV2-NGF to the nucleus basalis of Meynert is feasible, well-tolerated, and able to produce long-term, biologically active NGF expression, supporting the initiation of an ongoing multicenter, double-blind, sham-surgery-controlled trial.

**CONCLUSION**

Human gene therapy has advanced into a new stage where more and more investments will fuel more research and clinical trials. With a battery of AAV serotypes and variants and a series of well-established production and purification methods available to use, researchers and clinicians will be able to accelerate progress in the field. Though there are still some challenges ahead, more gene therapy drugs with AAV vectors are on the horizon.

**ACKNOWLEDGEMENTS**

I would like to thank Dr. Professor John Forsayeth, University of California, San Francisco, for his review and helpful comments.

**REFERENCES**

1 **Ylä-Herttuala S**. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. *Mol Ther* 2012; **20**: 1831-1832 [PMID: 23023051 DOI: 10.1038/mt.2012.194]

2 **Miller N**. Glybera and the future of gene therapy in the European Union. *Nat Rev Drug Discov* 2012; **11**: 419 [PMID: 22679644 DOI: 10.1038/nrd3572-c1]

3 **Herper M**. Gene therapy's big comeback. Forbes. [accessed 2014 Apr 14]. Available from: URL: http://www.forbes.com/sites/matthewherper/2014/03/26/once-seen-as-too-scary-editing-peoples-genes-with-viruses-makes-a-618-million-comeback/

4 **Xie Q**, Bu W, Bhatia S, Hare J, Somasundaram T, Azzi A, Chapman MS. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. *Proc Natl Acad Sci U S A* 2002; **99**: 10405-10410 [PMID: 12136130 DOI: 10.1073/pnas.162250899]

5 **Samulski RJ**, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, Hunter LA. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. *EMBO J* 1991; **10**: 3941-3950 [PMID: 1657596]

6 **Shelling AN**, Smith MG. Targeted integration of transfected and infected adeno-associated virus vectors containing the neomycin resistance gene. *Gene Ther* 1994; **1**: 165-169 [PMID: 7584077]

7 **Hoggan MD**, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. *Proc Natl Acad Sci USA* 1966; **55**: 1467-1474 [PMID: 5227666 DOI: 10.1073/pnas.55.6.1467]

8 **Atchison RW**, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. *Science* 1965; **149**: 754-756 [PMID: 14325163 DOI: 10.1126/science.149.3685.754]

9 **Parks WP**, Green M, Piña M, Melnick JL. Physicochemical characterization of adeno-associated satellite virus type 4 and its nucleic acid. *J Virol* 1967; **1**: 980-987 [PMID: 4987175]

10 **Bantel-Schaal U**, zur Hausen H. Characterization of the DNA of a defective human parvovirus isolated from a genital site. *Virology* 1984; **134**: 52-63 [PMID: 6324476 DOI: 10.1016/0042-6822(84)90271-X]

11 **Gao GP**, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. *Proc Natl Acad Sci USA* 2002; **99**: 11854-11859 [PMID: 12192090 DOI: 10.1073/pnas.182412299]

12 **Chao H**, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. *Mol Ther* 2000; **2**: 619-623 [PMID: 11124063 DOI: 10.1006/mthe.2000.0219]

13 **Xiao W**, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM. Gene therapy vectors based on adeno-associated virus type 1. *J Virol* 1999; **73**: 3994-4003 [PMID: 10196295]

14 **Sen D**, Balakrishnan B, Gabriel N, Agrawal P, Roshini V, Samuel R, Srivastava A, Jayandharan GR. Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy. *Sci Rep* 2013; **3**: 1832 [PMID: 23665951 DOI: 10.1038/srep01832]

15 **Hauck B**, Xiao W. Characterization of tissue tropism determinants of adeno-associated virus type 1. *J Virol* 2003; **77**: 2768-2774 [PMID: 12552020 DOI: 10.1128/JVI.77.4.2768-2774.2003]

16 **Sahenk Z**, Galloway G, Clark KR, Malik V, Rodino-Klapac LR, Kaspar BK, Chen L, Braganza C, Montgomery C, Mendell JR. AAV1.NT-3 gene therapy for charcot-marie-tooth neuropathy. *Mol Ther* 2014; **22**: 511-521 [PMID: 24162799 DOI: 10.1038/mt.2013.250]

17 **Tilemann L**, Lee A, Ishikawa K, Aguero J, Rapti K, Santos-Gallego C, Kohlbrenner E, Fish KM, Kho C, Hajjar RJ. SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure. *Sci Transl Med* 2013; **5**: 211ra159 [PMID: 24225946 DOI: 10.1126/scitranslmed.3006487]

18 **Vulin A**, Barthélémy I, Goyenvalle A, Thibaud JL, Beley C, Griffith G, Benchaouir R, le Hir M, Unterfinger Y, Lorain S, Dreyfus P, Voit T, Carlier P, Blot S, Garcia L. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. *Mol Ther* 2012; **20**: 2120-2133 [PMID: 22968479 DOI: 10.1038/mt.2012.181]

19 **Zsebo K**, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, Hajjar RJ. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. *Circ Res* 2014; **114**: 101-108 [PMID: 24065463 DOI: 10.1161/CIRCRESAHA.113.302421]

20 **Hajjar RJ**, Zsebo K, Deckelbaum L, Thompson C, Rudy J, Yaroshinsky A, Ly H, Kawase Y, Wagner K, Borow K, Jaski B, London B, Greenberg B, Pauly DF, Patten R, Starling R, Mancini D, Jessup M. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. *J Card Fail* 2008; **14**: 355-367 [PMID: 18514926 DOI: 10.1016/j.cardfail.2008.02.005]

21 **Jaski BE**, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, Borow K, Dittrich H, Zsebo KM, Hajjar RJ. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. *J Card Fail* 2009; **15**: 171-181 [PMID: 19327618 DOI: 10.1016/j.cardfail.2009.01.013]

22 **Srivastava A**, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. *J Virol* 1983; **45**: 555-564 [PMID: 6300419]

23 **Rabinowitz JE**, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. *J Virol* 2002; **76**: 791-801 [PMID: 11752169 DOI: 10.1128/JVI.76.2.791-801.2002]

24 **Kern A**, Schmidt K, Leder C, Müller OJ, Wobus CE, Bettinger K, Von der Lieth CW, King JA, Kleinschmidt JA. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. *J Virol* 2003; **77**: 11072-11081 [PMID: 14512555 DOI: 10.1128/JVI.77.20.11072-11081.2003]

25 **Petrs-Silva H**, Dinculescu A, Li Q, Min SH, Chiodo V, Pang JJ, Zhong L, Zolotukhin S, Srivastava A, Lewin AS, Hauswirth WW. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. *Mol Ther* 2009; **17**: 463-471 [PMID: 19066593 DOI: 10.1038/mt.2008.269]

26 **Nakai H**, Montini E, Fuess S, Storm TA, Grompe M, Kay MA. AAV serotype 2 vectors preferentially integrate into active genes in mice. *Nat Genet* 2003; **34**: 297-302 [PMID: 12778174 DOI: 10.1038/ng1179]

27 **Flotte T**, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, Taylor G, Walden S, Wetzel R. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. *Hum Gene Ther* 1996; **7**: 1145-1159 [PMID: 8773517 DOI: 10.1089/hum.1996.7.9-1145]

28 **Kay MA**, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. *Nat Genet* 2000; **24**: 257-261 [PMID: 10700178 DOI: 10.1038/73464]

29 **Maguire AM**, Simonelli F, Pierce EA, Pugh EN, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. Safety and efficacy of gene transfer for Leber's congenital amaurosis. *N Engl J Med* 2008; **358**: 2240-2248 [PMID: 18441370 DOI: 10.1056/NEJMoa0802315]

30 **Bainbridge JW**, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR. Effect of gene therapy on visual function in Leber's congenital amaurosis. *N Engl J Med* 2008; **358**: 2231-2239 [PMID: 18441371 DOI: 10.1056/NEJMoa0802268]

31 **Hauswirth WW**, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, Conlon TJ, Boye SL, Flotte TR, Byrne BJ, Jacobson SG. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. *Hum Gene Ther* 2008; **19**: 979-990 [PMID: 18774912 DOI: 10.1089/hum.2008.107]

32 **Christine CW**, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, VanBrocklin HF, Wright JF, Bankiewicz KS, Aminoff MJ. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. *Neurology* 2009; **73**: 1662-1669 [PMID: 19828868 DOI: 10.1212/WNL.0b013e3181c29356]

33 **McPhee SW**, Janson CG, Li C, Samulski RJ, Camp AS, Francis J, Shera D, Lioutermann L, Feely M, Freese A, Leone P. Immune responses to AAV in a phase I study for Canavan disease. *J Gene Med* 2006; **8**: 577-588 [PMID: 16532510 DOI: 10.1002/jgm.885]

34 **Feigin A**, Kaplitt MG, Tang C, Lin T, Mattis P, Dhawan V, During MJ, Eidelberg D. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. *Proc Natl Acad Sci USA* 2007; **104**: 19559-19564 [PMID: 18042721 DOI: 10.1073/pnas.0706006104]

35 **Kaplitt MG**, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. *Lancet* 2007; **369**: 2097-2105 [PMID: 17586305 DOI: 10.1016/S0140-6736(07)60982-9]

36 **Marks WJ**, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, Kordower JH, Olanow CW. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. *Lancet Neurol* 2010; **9**: 1164-1172 [PMID: 20970382 DOI: 10.1016/S1474-4422(10)70254-4]

37 **Muramatsu S**, Mizukami H, Young NS, Brown KE. Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. *Virology* 1996; **221**: 208-217 [PMID: 8661429 DOI: 10.1006/viro.1996.0367]

38 **Rutledge EA**, Halbert CL, Russell DW. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. *J Virol* 1998; **72**: 309-319 [PMID: 9420229]

39 **Lerch TF**, Chapman MS. Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). *Virology* 2012; **423**: 6-13 [PMID: 22169623 DOI: 10.1016/j.virol.2011.10.007]

40 **Cheng B**, Ling C, Dai Y, Lu Y, Glushakova LG, Gee SW, McGoogan KE, Aslanidi GV, Park M, Stacpoole PW, Siemann D, Liu C, Srivastava A, Ling C. Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. *Gene Ther* 2012; **19**: 375-384 [PMID: 21776025 DOI: 10.1038/gt.2011.105]

41 **Chiorini JA**, Yang L, Liu Y, Safer B, Kotin RM. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. *J Virol* 1997; **71**: 6823-6833 [PMID: 9261407]

42 **Davidson BL**, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA, Zabner J, Ghodsi A, Chiorini JA. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. *Proc Natl Acad Sci USA* 2000; **97**: 3428-3432 [PMID: 10688913 DOI: 10.1073/pnas.97.7.3428]

43 **Liu G**, Martins IH, Chiorini JA, Davidson BL. Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS. *Gene Ther* 2005; **12**: 1503-1508 [PMID: 15944733 DOI: 10.1038/sj.gt.3302554]

44 **Liu G**, Martins I, Wemmie JA, Chiorini JA, Davidson BL. Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. *J Neurosci* 2005; **25**: 9321-9327 [PMID: 16221840 DOI: 10.1523/JNEUROSCI.2936-05.2005]

45 **Dodge JC**, Treleaven CM, Fidler JA, Hester M, Haidet A, Handy C, Rao M, Eagle A, Matthews JC, Taksir TV, Cheng SH, Shihabuddin LS, Kaspar BK. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. *Mol Ther* 2010; **18**: 2075-2084 [PMID: 20859261 DOI: 10.1038/mt.2010.206]

46 **Le Meur G**, Stieger K, Smith AJ, Weber M, Deschamps JY, Nivard D, Mendes-Madeira A, Provost N, Péréon Y, Cherel Y, Ali RR, Hamel C, Moullier P, Rolling F. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. *Gene Ther* 2007; **14**: 292-303 [PMID: 17024105 DOI: 10.1038/sj.gt.3302861]

47 **Meur GL**, Pereon L, Rolling F, Weber M. Efficacy and safety of gene therapy with AAV4 in childhood blindness due to rpe65 mutations. *Acta Ophthalmologica* 2012; **90** [DOI: 10.1111/j.1755-3768.2012.4223.x]

48 **Schmidt M**, Katano H, Bossis I, Chiorini JA. Cloning and characterization of a bovine adeno-associated virus. *J Virol* 2004; **78**: 6509-6516 [PMID: 15163744 DOI: 10.1128/JVI.78.12.6509-6516.2004]

49 **Mason MR**, Ehlert EM, Eggers R, Pool CW, Hermening S, Huseinovic A, Timmermans E, Blits B, Verhaagen J. Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons. *Mol Ther* 2010; **18**: 715-724 [PMID: 20179682 DOI: 10.1038/mt.2010.19]

50 **Lin DS**, Hsiao CD, Liau I, Lin SP, Chiang MF, Chuang CK, Wang TJ, Wu TY, Jian YR, Huang SF, Liu HL. CNS-targeted AAV5 gene transfer results in global dispersal of vector and prevention of morphological and function deterioration in CNS of globoid cell leukodystrophy mouse model. *Mol Genet Metab* 2011; **103**: 367-377 [PMID: 21620749 DOI: 10.1016/j.ymgme.2011.05.005]

51 **Zabner J**, Seiler M, Walters R, Kotin RM, Fulgeras W, Davidson BL, Chiorini JA. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. *J Virol* 2000; **74**: 3852-3858 [PMID: 10729159 DOI: 10.1128/JVI.74.8.3852-3858.2000]

52 **Xin KQ**, Mizukami H, Urabe M, Toda Y, Shinoda K, Yoshida A, Oomura K, Kojima Y, Ichino M, Klinman D, Ozawa K, Okuda K. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. *J Virol* 2006; **80**: 11899-11910 [PMID: 17005662 DOI: 10.1128/JVI.00890-06]

53 **Halbert CL**, Allen JM, Miller AD. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. *J Virol* 2001; **75**: 6615-6624 [PMID: 11413329 DOI: 10.1128/JVI.75.14.6615-6624.2001]

54 **Gregorevic P**, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG, Russell DW, Chamberlain JS. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. *Nat Med* 2004; **10**: 828-834 [PMID: 15273747 DOI: 10.1038/nm1085]

55 **Odom GL**, Gregorevic P, Allen JM, Chamberlain JS. Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. *Mol Ther* 2011; **19**: 36-45 [PMID: 20859263 DOI: 10.1038/mt.2010.205]

56 **Pandya J**, Ortiz L, Ling C, Rivers AE, Aslanidi G. Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. *Immunol Cell Biol* 2014; **92**: 116-123 [PMID: 24217810 DOI: 10.1038/icb.2013.74]

57 **Wang Z**, Zhu T, Rehman KK, Bertera S, Zhang J, Chen C, Papworth G, Watkins S, Trucco M, Robbins PD, Li J, Xiao X. Widespread and stable pancreatic gene transfer by adeno-associated virus vectors via different routes. *Diabetes* 2006; **55**: 875-884 [PMID: 16567506 DOI: 10.2337/diabetes.55.04.06.db05-0927]

58 **Gao GP**, Lu Y, Sun X, Johnston J, Calcedo R, Grant R, Wilson JM. High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes. *J Virol* 2006; **80**: 6192-6194 [PMID: 16731960 DOI: 10.1128/JVI.00526-06]

59 **Samaranch L**, Salegio EA, San Sebastian W, Kells AP, Bringas JR, Forsayeth J, Bankiewicz KS. Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. *Hum Gene Ther* 2013; **24**: 526-532 [PMID: 23517473 DOI: 10.1089/hum.2013.005]

60 **Holehonnur R**, Luong JA, Chaturvedi D, Ho A, Lella SK, Hosek MP, Ploski JE. Adeno-associated viral serotypes produce differing titers and differentially transduce neurons within the rat basal and lateral amygdala. *BMC Neurosci* 2014; **15**: 28 [PMID: 24533621 DOI: 10.1186/1471-2202-15-28]

61 **Nam HJ**, Lane MD, Padron E, Gurda B, McKenna R, Kohlbrenner E, Aslanidi G, Byrne B, Muzyczka N, Zolotukhin S, Agbandje-McKenna M. Structure of adeno-associated virus serotype 8, a gene therapy vector. *J Virol* 2007; **81**: 12260-12271 [PMID: 17728238 DOI: 10.1128/JVI.01304-07]

62 **Sarkar R**, Tetreault R, Gao G, Wang L, Bell P, Chandler R, Wilson JM, Kazazian HH. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. *Blood* 2004; **103**: 1253-1260 [PMID: 14551134 DOI: 10.1182/blood-2003-08-2954]

63 **Lebherz C**, Gao G, Louboutin JP, Millar J, Rader D, Wilson JM. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. *J Gene Med* 2004; **6**: 663-672 [PMID: 15170737 DOI: 10.1002/jgm.554]

64 **Sun B**, Zhang H, Franco LM, Young SP, Schneider A, Bird A, Amalfitano A, Chen YT, Koeberl DD. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. *Mol Ther* 2005; **11**: 57-65 [PMID: 15585406 DOI: 10.1016/j.ymthe.2004.10.004]

65 **Wang L**, Calcedo R, Nichols TC, Bellinger DA, Dillow A, Verma IM, Wilson JM. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. *Blood* 2005; **105**: 3079-3086 [PMID: 15637142 DOI: 10.1182/blood-2004-10-3867]

66 **Wang Z**, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, Chen C, Li J, Xiao X. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. *Nat Biotechnol* 2005; **23**: 321-328 [PMID: 15735640 DOI: 10.1038/nbt1073]

67 **Lisowski L**, Dane AP, Chu K, Zhang Y, Cunningham SC, Wilson EM, Nygaard S, Grompe M, Alexander IE, Kay MA. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. *Nature* 2014; **506**: 382-386 [PMID: 24390344 DOI: 10.1038/nature12875]

68 **Gao G**, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM. Clades of Adeno-associated viruses are widely disseminated in human tissues. *J Virol* 2004; **78**: 6381-6388 [PMID: 15163731 DOI: 10.1128/JVI.78.12.6381-6388.2004]

69 **DiMattia MA**, Nam HJ, Van Vliet K, Mitchell M, Bennett A, Gurda BL, McKenna R, Olson NH, Sinkovits RS, Potter M, Byrne BJ, Aslanidi G, Zolotukhin S, Muzyczka N, Baker TS, Agbandje-McKenna M. Structural insight into the unique properties of adeno-associated virus serotype 9. *J Virol* 2012; **86**: 6947-6958 [PMID: 22496238 DOI: 10.1128/JVI.07232-11]

70 **Bish LT**, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao G, Wilson JM, Sweeney HL. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. *Hum Gene Ther* 2008; **19**: 1359-1368 [PMID: 18795839 DOI: 10.1089/hum.2008.123]

71 **Inagaki K**, Fuess S, Storm TA, Gibson GA, Mctiernan CF, Kay MA, Nakai H. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. *Mol Ther* 2006; **14**: 45-53 [PMID: 16713360 DOI: 10.1016/j.ymthe.2006.03.014]

72 **Pleger ST**, Shan C, Ksienzyk J, Bekeredjian R, Boekstegers P, Hinkel R, Schinkel S, Leuchs B, Ludwig J, Qiu G, Weber C, Raake P, Koch WJ, Katus HA, Müller OJ, Most P. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. *Sci Transl Med* 2011; **3**: 92ra64 [PMID: 21775667 DOI: 10.1126/scitranslmed.3002097]

73 **Bucher T**, Dubreil L, Colle MA, Maquigneau M, Deniaud J, Ledevin M, Moullier P, Joussemet B. Intracisternal delivery of AAV9 results in oligodendrocyte and motor neuron transduction in the whole central nervous system of cats. *Gene Ther* 2014; **21**: 522-528 [PMID: 24572783 DOI: 10.1038/gt.2014.16]

74 **Ciesielska A**, Hadaczek P, Mittermeyer G, Zhou S, Wright JF, Bankiewicz KS, Forsayeth J. Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. *Mol Ther* 2013; **21**: 158-166 [PMID: 22929660 DOI: 10.1038/mt.2012.167]

75 **Mendell JR**. Gene transfer clinical trial for spinal muscular atrophy type 1. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: URL: <https://clinicaltrials.gov/ct2/show/NCT02122952> NLM Identifier: NCT02122952

76 **Klimczak RR**, Koerber JT, Dalkara D, Flannery JG, Schaffer DV. A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Müller cells. *PLoS One* 2009; **4**: e7467 [PMID: 19826483 DOI: 10.1371/journal.pone.0007467]

77 **Dalkara D**, Kolstad KD, Guerin KI, Hoffmann NV, Visel M, Klimczak RR, Schaffer DV, Flannery JG. AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa. *Mol Ther* 2011; **19**: 1602-1608 [PMID: 21522134 DOI: 10.1038/mt.2011.62]

78 **Vacca O**, Darche M, Schaffer DV, Flannery JG, Sahel JA, Rendon A, Dalkara D. AAV-mediated gene delivery in Dp71-null mouse model with compromised barriers. *Glia* 2014; **62**: 468-476 [PMID: 24382652 DOI: 10.1002/glia.22617]

79 **Dalkara D**, Byrne LC, Klimczak RR, Visel M, Yin L, Merigan WH, Flannery JG, Schaffer DV. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. *Sci Transl Med* 2013; **5**: 189ra76 [PMID: 23761039 DOI: 10.1126/scitranslmed.3005708]

80 **Macé E**, Caplette R, Marre O, Sengupta A, Chaffiol A, Barbe P, Desrosiers M, Bamberg E, Sahel JA, Picaud S, Duebel J, Dalkara D. Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV Restores ON and OFF visual responses in blind mice. *Mol Ther* 2015; **23**: 7-16 [PMID: 25095892 DOI: 10.1038/mt.2014.154]

81 **Grimm D**, Lee JS, Wang L, Desai T, Akache B, Storm TA, Kay MA. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. *J Virol* 2008; **82**: 5887-5911 [PMID: 18400866 DOI: 10.1128/JVI.00254-08]

82 **Berns KI**, Rose JA. Evidence for a single-stranded adenovirus-associated virus genome: isolation and separation of complementary single strands. *J Virol* 1970; **5**: 693-699 [PMID: 5429749]

83 **Rose JA**, Berns KI, Hoggan MD, Koczot FJ. Evidence for a single-stranded adenovirus-associated virus genome: formation of a DNA density hybrid on release of viral DNA. *Proc Natl Acad Sci USA* 1969; **64**: 863-869 [PMID: 5264145 DOI: 10.1073/pnas.64.3.863]

84 **Hirata RK**, Russell DW. Design and packaging of adeno-associated virus gene targeting vectors. *J Virol* 2000; **74**: 4612-4620 [PMID: 10775597 DOI: 10.1128/JVI.74.10.4612-4620.2000]

85 **McCarty DM**, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. *Gene Ther* 2001; **8**: 1248-1254 [PMID: 11509958 DOI: 10.1038/sj.gt.3301514]

86 **McCarty DM**, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. *Gene Ther* 2003; **10**: 2112-2118 [PMID: 14625565 DOI: 10.1038/sj.gt.3302134]

87 **Wang Z**, Ma HI, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. *Gene Ther* 2003; **10**: 2105-2111 [PMID: 14625564 DOI: 10.1038/sj.gt.3302133]

88 **Nathwani AC**, Gray JT, Ng CY, Zhou J, Spence Y, Waddington SN, Tuddenham EG, Kemball-Cook G, McIntosh J, Boon-Spijker M, Mertens K, Davidoff AM. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. *Blood* 2006; **107**: 2653-2661 [PMID: 16322469 DOI: 10.1182/blood-2005-10-4035]

89 **Goyenvalle A**, Babbs A, Wright J, Wilkins V, Powell D, Garcia L, Davies KE. Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping. *Hum Mol Genet* 2012; **21**: 2559-2571 [PMID: 22388933 DOI: 10.1093/hmg/dds082]

90 **Yang X**, Haurigot V, Zhou S, Luo G, Couto LB. Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus microRNA cluster. *Hepatology* 2010; **52**: 1877-1887 [PMID: 20931557 DOI: 10.1002/hep.23908]

91 **Muzyczka N**. Use of adeno-associated virus as a general transduction vector for mammalian cells. *Curr Top Microbiol Immunol* 1992; **158**: 97-129 [PMID: 1316261]

92 **Matsushita T**, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman GJ, Iwaki Y, Colosi P. Adeno-associated virus vectors can be efficiently produced without helper virus. *Gene Ther* 1998; **5**: 938-945 [PMID: 9813665]

93 **Xiao X**, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. *J Virol* 1998; **72**: 2224-2232 [PMID: 9499080]

94 **Grimm D**, Kay MA, Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. *Mol Ther* 2003; **7**: 839-850 [PMID: 12788658 DOI: 10.1016/S1525-0016(03)00095-9]

95 **Lock M**, Alvira M, Vandenberghe LH, Samanta A, Toelen J, Debyser Z, Wilson JM. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. *Hum Gene Ther* 2010; **21**: 1259-1271 [PMID: 20497038 DOI: 10.1089/hum.2010.055]

96 **Park JY**, Lim BP, Lee K, Kim YG, Jo EC. Scalable production of adeno-associated virus type 2 vectors via suspension transfection. *Biotechnol Bioeng* 2006; **94**: 416-430 [PMID: 16622883 DOI: 10.1002/bit.20776]

97 **Durocher Y**, Pham PL, St-Laurent G, Jacob D, Cass B, Chahal P, Lau CJ, Nalbantoglu J, Kamen A. Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells. *J Virol Methods* 2007; **144**: 32-40 [PMID: 17467815 DOI: 10.1016/j.jviromet.2007.03.014]

98 **Tamayose K**, Hirai Y, Shimada T. A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. *Hum Gene Ther* 1996; **7**: 507-513 [PMID: 8800745 DOI: 10.1089/hum.1996.7.4-507]

99 **Clark KR**, Voulgaropoulou F, Fraley DM, Johnson PR. Cell lines for the production of recombinant adeno-associated virus. *Hum Gene Ther* 1995; **6**: 1329-1341 [PMID: 8590738 DOI: 10.1089/hum.1995.6.10-1329]

100 **Liu XL**, Clark KR, Johnson PR. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. *Gene Ther* 1999; **6**: 293-299 [PMID: 10435114]

101 **Fisher KJ**, Kelley WM, Burda JF, Wilson JM. A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. *Hum Gene Ther* 1996; **7**: 2079-2087 [PMID: 8934222 DOI: 10.1089/hum.1996.7.17-2079]

102 **Inoue N**, Russell DW. Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. *J Virol* 1998; **72**: 7024-7031 [PMID: 9696794]

103 **Gao GP**, Lu F, Sanmiguel JC, Tran PT, Abbas Z, Lynd KS, Marsh J, Spinner NB, Wilson JM. Rep/Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. *Mol Ther* 2002; **5**: 644-649 [PMID: 11991756 DOI: 10.1006/mthe.2001.0591]

104 **Conway JE**, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. *J Virol* 1997; **71**: 8780-8789 [PMID: 9343238]

105 **Booth MJ**, Mistry A, Li X, Thrasher A, Coffin RS. Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids. *Gene Ther* 2004; **11**: 829-837 [PMID: 14985784 DOI: 10.1038/sj.gt.3302226]

106 **Thomas DL**, Wang L, Niamke J, Liu J, Kang W, Scotti MM, Ye GJ, Veres G, Knop DR. Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells. *Hum Gene Ther* 2009; **20**: 861-870 [PMID: 19419276 DOI: 10.1089/hum.2009.004]

107 **Urabe M**, Ding C, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. *Hum Gene Ther* 2002; **13**: 1935-1943 [PMID: 12427305 DOI: 10.1089/10430340260355347]

108 **Kohlbrenner E**, Aslanidi G, Nash K, Shklyaev S, Campbell-Thompson M, Byrne BJ, Snyder RO, Muzyczka N, Warrington KH, Zolotukhin S. Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. *Mol Ther* 2005; **12**: 1217-1225 [PMID: 16213797 DOI: 10.1016/j.ymthe.2005.08.018]

109 **Smith RH**, Levy JR, Kotin RM. A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. *Mol Ther* 2009; **17**: 1888-1896 [PMID: 19532142 DOI: 10.1038/mt.2009.128]

110 **Merten OW**, Gény-Fiamma C, Douar AM. Current issues in adeno-associated viral vector production. *Gene Ther* 2005; **12** Suppl 1: S51-S61 [PMID: 16231056 DOI: 10.1038/sj.gt.3302615]

111 **Urabe M**, Nakakura T, Xin KQ, Obara Y, Mizukami H, Kume A, Kotin RM, Ozawa K. Scalable generation of high-titer recombinant adeno-associated virus type 5 in insect cells. *J Virol* 2006; **80**: 1874-1885 [PMID: 16439543 DOI: 10.1128/JVI.80.4.1874-1885.2006]

112 **Chen H**. Intron splicing-mediated expression of AAV Rep and Cap genes and production of AAV vectors in insect cells. *Mol Ther* 2008; **16**: 924-930 [PMID: 18388928 DOI: 10.1038/mt.2008.35]

113 **Cecchini S**, Virag T, Kotin RM. Reproducible high yields of recombinant adeno-associated virus produced using invertebrate cells in 0.02- to 200-liter cultures. *Hum Gene Ther* 2011; **22**: 1021-1030 [PMID: 21381980 DOI: 10.1089/hum.2010.250]

114 **Girod A**, Wobus CE, Zádori Z, Ried M, Leike K, Tijssen P, Kleinschmidt JA, Hallek M. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. *J Gen Virol* 2002; **83**: 973-978 [PMID: 11961250 DOI: 10.1099/vir.0.18108-0]

115 **Stahnke S**, Lux K, Uhrig S, Kreppel F, Hösel M, Coutelle O, Ogris M, Hallek M, Büning H. Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles. *Virology* 2011; **409**: 77-83 [PMID: 20974479 DOI: 10.1016/j.virol.2010.09.025]

116 **Popa-Wagner R**, Porwal M, Kann M, Reuss M, Weimer M, Florin L, Kleinschmidt JA. Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry. *J Virol* 2012; **86**: 9163-9174 [PMID: 22696661 DOI: 10.1128/JVI.00282-12]

117 **Chen H**. Exploiting the Intron-splicing Mechanism of Insect Cells to Produce Viral Vectors Harboring Toxic Genes for Suicide Gene Therapy. *Mol Ther Nucleic Acids* 2012; **1**: e57 [PMID: 23187456 DOI: 10.1038/mtna.2012.48]

118 **Green M**, Pina M. Biochemical studies on adenovirus multiplication, vi. properties of highly purified tumorigenic human adenoviruses and their DNA. *Proc Natl Acad Sci U S A* 1964; **51**: 1251-1259 [PMID: 14215651 DOI: 10.1073/pnas.51.6.1251]

119 **Burova E**, Ioffe E. Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications. *Gene Ther* 2005; **12** Suppl 1: S5-17 [PMID: 16231055 DOI: 10.1038/sj.gt.3302611]

120 **Davidoff AM**, Ng CY, Sleep S, Gray J, Azam S, Zhao Y, McIntosh JH, Karimipoor M, Nathwani AC. Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. *J Virol Methods* 2004; **121**: 209-215 [PMID: 15381358 DOI: 10.1016/j.jviromet.2004.07.001]

121 **Gao G**, Qu G, Burnham MS, Huang J, Chirmule N, Joshi B, Yu QC, Marsh JA, Conceicao CM, Wilson JM. Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. *Hum Gene Ther* 2000; **11**: 2079-2091 [PMID: 11044910 DOI: 10.1089/104303400750001390]

122 **Smith RH**, Yang L, Kotin RM. Chromatography-based purification of adeno-associated virus. *Methods Mol Biol* 2008; **434**: 37-54 [PMID: 18470638 DOI: 10.1007/978-1-60327-248-3\_4]

123 **Zhou J**, Yang X, Wright JF, High KA, Couto L, Qu G. PEG-modulated column chromatography for purification of recombinant adeno-associated virus serotype 9. *J Virol Methods* 2011; **173**: 99-107 [PMID: 21295608 DOI: 10.1016/j.jviromet.2011.01.013]

124 **Anderson R**, Macdonald I, Corbett T, Whiteway A, Prentice HG. A method for the preparation of highly purified adeno-associated virus using affinity column chromatography, protease digestion and solvent extraction. *J Virol Methods* 2000; **85**: 23-34 [PMID: 10716335 DOI: 10.1016/S0166-0934(99)00150-0]

125 **Zolotukhin S**, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. *Gene Ther* 1999; **6**: 973-985 [PMID: 10455399 DOI: 10.1038/sj.gt.3300938]

126 **Ayuso E**, Mingozzi F, Montane J, Leon X, Anguela XM, Haurigot V, Edmonson SA, Africa L, Zhou S, High KA, Bosch F, Wright JF. High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. *Gene Ther* 2010; **17**: 503-510 [PMID: 19956269 DOI: 10.1038/gt.2009.157]

127 **Wright JF**. Adeno-associated virus vectors to support clinical studies. 2008. Available from: URL: https: //www.gtrp.org/docs/CHOP AAV Lab\_5.28.08.ppt

128 **Hermens WT**, ter Brake O, Dijkhuizen PA, Sonnemans MA, Grimm D, Kleinschmidt JA, Verhaagen J. Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. *Hum Gene Ther* 1999; **10**: 1885-1891 [PMID: 10446928 DOI: 10.1089/10430349950017563]

129 **Brument N**, Morenweiser R, Blouin V, Toublanc E, Raimbaud I, Chérel Y, Folliot S, Gaden F, Boulanger P, Kroner-Lux G, Moullier P, Rolling F, Salvetti A. A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5. *Mol Ther* 2002; **6**: 678-686 [PMID: 12436964 DOI: 10.1006/mthe.2002.0719]

130 **Qu G**, Bahr-Davidson J, Prado J, Tai A, Cataniag F, McDonnell J, Zhou J, Hauck B, Luna J, Sommer JM, Smith P, Zhou S, Colosi P, High KA, Pierce GF, Wright JF. Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. *J Virol Methods* 2007; **140**: 183-192 [PMID: 17196264 DOI: 10.1016/j.jviromet.2006.11.019]

131 **Wu X**, Dong X, Wu Z, Cao H, Niu D, Qu J, Wang H, and Hou Y. A novel method for purification of recombinant adenoassociated virus vectors on a large scale. *Chinese Science Bulletin* 2001; **46**: 485-488 [DOI: 10.1007/BF03187263]

132 **Guo P**, El-Gohary Y, Prasadan K, Shiota C, Xiao X, Wiersch J, Paredes J, Tulachan S, Gittes GK. Rapid and simplified purification of recombinant adeno-associated virus. *J Virol Methods* 2012; **183**: 139-146 [PMID: 22561982 DOI: 10.1016/j.jviromet.2012.04.004]

133 **Edelstein M**. Gene therapy clinical trials worldwide. *J Gene Med* 2015. Available from: URL: http://www.abedia.com/wiley/vectors.php

134 **Daly TM**, Vogler C, Levy B, Haskins ME, Sands MS. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. *Proc Natl Acad Sci USA* 1999; **96**: 2296-2300 [PMID: 10051635 DOI: 10.1073/pnas.96.5.2296]

135 **Boye SE**, Boye SL, Lewin AS, Hauswirth WW. A comprehensive review of retinal gene therapy. *Mol Ther* 2013; **21**: 509-519 [PMID: 23358189 DOI: 10.1038/mt.2012.280]

136 **Naim C**, Yerevanian A, Hajjar RJ. Gene therapy for heart failure: where do we stand? *Curr Cardiol Rep* 2013; **15**: 333 [PMID: 23307169 DOI: 10.1007/s11886-012-0333-3]

137 **Bartus RT**, Baumann TL, Brown L, Kruegel BR, Ostrove JM, Herzog CD. Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease. *Neurobiol Aging* 2013; **34**: 35-61 [PMID: 22926166 DOI: 10.1016/j.neurobiolaging.2012.07.018]

138 **Mandel RJ**, Spratt SK, Snyder RO, Leff SE. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. *Proc Natl Acad Sci USA* 1997; **94**: 14083-14088 [PMID: 9391156]

139 **Cideciyan AV**, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, Pang JJ, Sumaroka A, Windsor EA, Wilson JM, Flotte TR, Fishman GA, Heon E, Stone EM, Byrne BJ, Jacobson SG, Hauswirth WW. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. *Proc Natl Acad Sci USA* 2008; **105**: 15112-15117 [PMID: 18809924 DOI: 10.1073/pnas.0807027105]

140 **Manno CS**, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, Tai SJ, Ragni MV, Thompson A, Ozelo M, Couto LB, Leonard DG, Johnson FA, McClelland A, Scallan C, Skarsgard E, Flake AW, Kay MA, High KA, Glader B. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. *Blood* 2003; **101**: 2963-2972 [PMID: 12515715 DOI: 10.1182/blood-2002-10-3296]

141 **Manno CS**, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. *Nat Med* 2006; **12**: 342-347 [PMID: 16474400 DOI: 10.1038/nm1358]

142 **Hasbrouck NC**, High KA. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects. *Gene Ther* 2008; **15**: 870-875 [PMID: 18432276 DOI: 10.1038/gt.2008.71]

143 **Nathwani AC**, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. *N Engl J Med* 2011; **365**: 2357-2365 [PMID: 22149959 DOI: 10.1056/NEJMoa1108046]

144 **Jessup M**, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. *Circulation* 2011; **124**: 304-313 [PMID: 21709064 DOI: 10.1161/CIRCULATIONAHA.111.022889]

145 **Bartus RT**, Weinberg MS, Samulski RJ. Parkinson's disease gene therapy: success by design meets failure by efficacy. *Mol Ther* 2014; **22**: 487-497 [PMID: 24356252 DOI: 10.1038/mt.2013.281]

146 **Rafii MS**, Baumann TL, Bakay RA, Ostrove JM, Siffert J, Fleisher AS, Herzog CD, Barba D, Pay M, Salmon DP, Chu Y, Kordower JH, Bishop K, Keator D, Potkin S, Bartus RT. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. *Alzheimers Dement* 2014; **10**: 571-581 [PMID: 24411134 DOI: 10.1016/j.jalz.2013.09.004]

147 **Mandel RJ**. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. *Curr Opin Mol Ther* 2010; **12**: 240-247 [PMID: 20373268]

148 **Im DS**, Muzyczka N. The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity. *Cell* 1990; **61**: 447-457 [PMID: 2159383 DOI: 10.1016/0092-8674(90)90526-K]

149 **Leonard CJ**, Berns KI. Cloning, expression, and partial purification of Rep78: an adeno-associated virus replication protein. *Virology* 1994; **200**: 566-573 [PMID: 8178443 DOI: 10.1006/viro.1994.1219]

150 **Im DS**, Muzyczka N. Partial purification of adeno-associated virus Rep78, Rep52, and Rep40 and their biochemical characterization. *J Virol* 1992; **66**: 1119-1128 [PMID: 1309894]


151 **King JA**, Dubielzig R, Grimm D, Kleinschmidt JA. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. *EMBO J* 2001; **20**: 3282-3291 [PMID: 11406604]

152 **Becerra SP**, Koczot F, Fabisch P, Rose JA. Synthesis of adeno-associated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript. *J Virol* 1988; **62**: 2745-2754 [PMID: 2839699]


153 **Grieger JC**, Johnson JS, Gurda-Whitaker B, Agbandje-McKenna M, Samulski RJ. Surface-exposed adeno-associated virus Vp1-NLS capsid fusion protein rescues infectivity of noninfectious wild-type Vp2/Vp3 and Vp3-only capsids but not that of fivefold pore mutant virions. *J Virol* 2007; **81**: 7833-7843 [PMID: 17507473 DOI: 10.1128/JVI.00580-07]

154 **Sonntag F**, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. *Proc Natl Acad Sci U S A* 2010; **107**: 10220-10225 [PMID: 20479244 DOI: 10.1073/pnas.1001673107]


**P-Reviewer:** Panda C, Song LT, Takenaga K **S-Editor:** Ji FF **L-Editor: E-Editor:**



**Figure 1 Diagram of adeno-associated virus genome depicting the inverted terminal repeats, promoters, polyadenylation sequence, and mRNAs coding for rep, cap, and assembly-activating protein proteins.** The rep ORF codes for four rep proteins (Rep78, Rep68, Rep52, and Rep40) that are synthesized from mRNAs transcribed from the p5 and p19 promoters. Rep78 and Rep68 have site-specific endonuclease, DNA helicase, and ATPase activities that are required for AAV DNA replication[148-150]. Rep52 and Rep40 contain helicase activity and are required for packaging adeno-associated virus (AAV) DNA into the capsids[151]. VP1, VP2, and VP3 are synthesized from mRNA transcribed from the p40 promoter. To main a 1:1:10 ratio of VP1:VP2:VP3 for virus particle assembly, AAV uses an alternative splicing mechanism for VP1 and a less efficient start codon (ACG) for VP2 to lower their protein levels, yet keeps high efficiency start codon (ATG) for VP3[152]. The N-terminal sequence present in VP1 contains a phospholipase A2 domain that is required for AAV infectivity[114,115,153]. In addition, the VP2/VP3 mRNA codes for an assembly-activating protein (AAP) from a weak CTG start codon but in a different reading frame[154]. AAP facilitates nuclear import of the major VP3 capsid protein and promotes assembly and maturation of the capsid, but AAP is not present in the mature capsid. ITR: Inverted terminal repeat; poly A: Polyadenylation.



**Figure 2 Diagram of adeno-associated virus vector production.** (A) The expression cassette containing promoter, intron, target gene, and polyadenylation sequence is flanked with adeno-associated virus (AAV) inverted terminal repeats (ITRs); (B) AAV rep and cap sequences without ITRs are provided *in trans*; and (C) helper virus can be adenovirus, HSV, or baculovirus depending on the production system used. Once these three components are introduced into a host cell under proper conditions, AAV vectors will be produced.



**Figure 3 SimplyBlue SafeStaining of purified adeno-associated virus vectors on SDS-PAGE gel.** Seven purified lots of adeno-associated virus (AAV) vectors at the amount of 1e + 11 vg per lane were loaded on a 10% Tris-glycine gel. The gel was stained with SimplyBlue SafeStain Kit (Invitrogen). Lanes 1: 4-6, AAV9; lanes 2 and 3: AAV5; lane 7: AAV8.2. AAV capsid proteins VP1, VP2, and VP3 are indicated; M: Protein ladders.

**Table 1 Properties and applications of the commonly used adeno-associated virus serotypes and variants**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| AAV serotypes and variants | Target tissues | Preclinical applications | Clinical applications | Ref. |
| AAV1 | Muscle,  heart | Charcot-Marie-Tooth Neuropathy,  congestive heart failure, Duchenne muscular dystrophy | Glybera, a drug for lipoprotein lipase deficiency, congenital heart failure | [1,2,11,15-17,19-21] |
| AAV2 | Liver, eye | *In vitro* assays, various animal model studies | Cystic fibrosis; hemophilia B,  Leber’s congenital amourosis, Parkinson’s disease; Canavan disease | [11,26-36] |
| AAV3A, 3B | Liver cancer | Liver cancer |  | [40] |
| AAV4 | Ependyma, astrocyte, retinal pigmented epithelium | Mucopolysaccharidosis type VII, Familial amyotrophic lateral sclerosis, RPE65-deficient vision loss | RPE65-deficient disease | [42,47] |
| AAV5 | Sesory neuron, airway epithelia, Dentritic cells | Globoid cell leukodystrophy; human immunodificiency | - | [49-52] |
| AAV6 | Airway epithelia, skeletal muscle, Dendritic cells, pancreatic beta cells | Duchenne muscular dystrophy | - | [53-56] |
| AAV7 | Skeletal muscle, liver, central nervous system | - | - | [11,58-60] |
| AAV8 | Liver, skeletal and cardiac muscle | Hemophilia A, familial hypercholesterolemia, glycogen storage disease type II, | Hemophilia B | [11,62-66,143] |
| AAV9 | Cardiac muscle, central nervous system | Heart failure, central nervous system disorders | Spinal muscular atrophy | [70-75] |
| AAVShH10 | Müller cells | Retinitis pigmentosa | - | [76,77, |
| AAV7m8 | Vitreous humor | Retinoschisis, Leber’s congenital amaurosis | - | 79,80] |
| AAVDJ | Liver, kidney, cervix, retina, oveary, skin, fibroblast, lung | - | - | [81] |

AAV: Adeno-associated virus.